Stock Financial Ratios, Dividends, Split History

CASI / CASI Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price6.72
Volume302,400.00
Market Cap ($M)578.90
Enterprise Value ($M)506.04
Book Value ($M)38.54
Book Value / Share0.78
Price / Book14.90
NCAV ($M)14.94
NCAV / Share0.56
Price / NCAV12.24
Share Statistics
Common Shares Outstanding 79,641,876
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.28
Return on Assets (ROA)-0.39
Return on Equity (ROE)-0.52
Balance Sheet (mrq) ($M)
Assets71.16
Liabilities3.54
Quick Ration/a
Current Ratio25.48
Income Statement (mra) ($M)
Revenues0.00
Sales Revenue Net0.00
Other Sales Revenue Net0.00
Royalty Revenue0.00
Net Income-10.77
Earnings Per Share Basic And Diluted-0.17
Cash Flow Statement (mra) ($M)
Cash From Operations-6.40
Cash from Investing-0.93
Cash from Financing-0.93
Identifiers and Descriptors
CUSIP14757U109
Central Index Key (CIK)895051

Split History

Stock splits are used by CASI Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Spectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good day, ladies and gentlemen, and welcome to Spectrum Pharmaceuticals First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, today’s conference is being recorded. (10-2)

Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center

2018-03-25 seekingalpha
James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area. A groundbreaking ceremony was held last Friday with Dr. Watson in attendance. The new research center, which may be called the Watson Research Center of Life Science, will strive to find new, less expensive solutions to the problem of cancer and will be staffed by more than 1,000 scientists. (18-0)

Your Daily Pharma Scoop: Arena Soars, Roche Data, GlaxoSmithKline Commences Study

2018-03-21 seekingalpha
GlaxoSmithKline commences late stage study with Benlysta (belimumab) and Roche's Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). (26-1)

BRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive Chairman

2018-02-09 reuters
* CASI PHARMACEUTICALS - ON FEB 7, BOARD APPROVED APPOINTMENT OF WEI-WU HE, CURRENT CHAIRMAN OF BOARD, AS EXECUTIVE CHAIRMAN - SEC FILING Source text: (bit.ly/2EUtR7g) Further company coverage: (10-0)

Week In Review: C-Bridge Raising Another $650 Million For China Healthcare

2018-02-04 seekingalpha
Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million. Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million. C-Bridge focuses on PE capital because it believes later-stage companies are currently the most promising investment sector in China healthcare. The company emphasizes China investments, but considers itself a global investor. (35-1)

CUSIP: 14757U109